Trevi Therapeutics IncNASDAQ:TRVI
- LAST PRICE2.7700
- TODAY'S CHANGE (%)-0.0700 (-2.4648%)
- Bid / Lots1.9200/ 4
- Ask / Lots2.9900/ 4
- Open / Previous Close2.8500 / 2.8400
- Day Range
- 52 Week Range
- Volume66,965
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRVI |
|---|---|---|
| 09:32 ET | 8841 | 2.765 |
| 10:01 ET | 1699 | 2.8 |
| 10:35 ET | 845 | 2.83 |
| 10:53 ET | 100 | 2.86 |
| 10:57 ET | 2000 | 2.91 |
| 11:00 ET | 100 | 2.91 |
| 11:02 ET | 100 | 2.93 |
| 11:09 ET | 1331 | 2.93 |
| 11:11 ET | 4332 | 2.9101 |
| 11:13 ET | 100 | 2.91 |
| 11:18 ET | 400 | 2.915 |
| 11:26 ET | 100 | 2.9 |
| 11:31 ET | 400 | 2.91 |
| 11:38 ET | 100 | 2.905 |
| 11:42 ET | 700 | 2.91 |
| 12:02 ET | 4731 | 2.83 |
| 12:05 ET | 100 | 2.855 |
| 12:20 ET | 300 | 2.83 |
| 12:25 ET | 700 | 2.835 |
| 12:36 ET | 100 | 2.835 |
| 12:41 ET | 100 | 2.82 |
| 12:52 ET | 500 | 2.79 |
| 12:56 ET | 100 | 2.79 |
| 01:10 ET | 225 | 2.79 |
| 02:08 ET | 100 | 2.7989 |
| 02:26 ET | 600 | 2.77 |
| 02:33 ET | 5001 | 2.77 |
| 02:36 ET | 300 | 2.78 |
| 02:38 ET | 1020 | 2.79 |
| 02:40 ET | 585 | 2.78 |
| 02:42 ET | 100 | 2.78 |
| 02:45 ET | 599 | 2.76 |
| 03:02 ET | 100 | 2.76 |
| 03:12 ET | 100 | 2.76 |
| 03:16 ET | 100 | 2.75 |
| 03:18 ET | 300 | 2.77 |
| 03:21 ET | 200 | 2.765 |
| 03:23 ET | 100 | 2.76 |
| 03:25 ET | 100 | 2.76 |
| 03:30 ET | 100 | 2.765 |
| 03:32 ET | 300 | 2.75 |
| 03:50 ET | 926 | 2.78 |
| 03:52 ET | 509 | 2.77 |
| 03:54 ET | 917 | 2.77 |
| 03:56 ET | 100 | 2.77 |
| 03:59 ET | 12170 | 2.77 |
May 9, 2024
Trevi Therapeutics to Participate in Upcoming Conferences, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
DJ Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham, from 9:37AM ET on Wednesday May 08, 2024 by Dow Jones
9:37AM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Press Release: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates, from 4:07PM ET on Tuesday May 07, 2024 by Dow Jones
4:07PM ET on Tuesday May 07, 2024 by Dow JonesTrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
May 1, 2024
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024, from 4:05PM ET on Wednesday May 01, 2024 by Dow Jones
4:05PM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Trevi Therapeutics Inc | 195.1M | -8.2x | --- |
Atossa Therapeutics Inc | 196.7M | -6.7x | --- |
Elevation Oncology Inc | 197.2M | -3.5x | --- |
Cytodyn Inc | 198.7M | -3.6x | --- |
Omeros Corp | 199.9M | -1.2x | --- |
Galectin Therapeutics Inc | 199.9M | -4.4x | --- |
Company Information
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Contact Information
- Headquarters
- 195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009
- Phone
- 203-304-2499
- Fax
- 203-304-2434
Executives
- Non-Executive Chairman of the Board
- David Meeker
- President, Chief Executive Officer, Director
- Jennifer Good
- Co-Founder, Chief Science Officer
- Thomas Sciascia
- Chief Financial Officer
- Lisa Delfini
- Chief Medical Officer
- David Clark
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $195.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-0.34 |
Book Value | $1.21 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
